161 related articles for article (PubMed ID: 38558740)
1. Development of the Emirates Multi-Criteria Decision Analysis Tool for Orphan Drugs.
Alnaqbi KA; Elezbawy B; Fasseeh AN; Bangash AR; Elshamy A; Shendi H; Aftab MI; AlMarshoodi M; Gebran N; AlDhaheri N; Fahmy SA; Al Dallal S; Al Naeem W; Abaza S; Kaló Z
Cureus; 2024 Feb; 16(2):e55215. PubMed ID: 38558740
[TBL] [Abstract][Full Text] [Related]
2. Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut).
Guarga L; Badia X; Obach M; Fontanet M; Prat A; Vallano A; Torrent J; Pontes C
Orphanet J Rare Dis; 2019 Jun; 14(1):157. PubMed ID: 31248421
[TBL] [Abstract][Full Text] [Related]
3. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs.
Schey C; Krabbe PF; Postma MJ; Connolly MP
Orphanet J Rare Dis; 2017 Jan; 12(1):10. PubMed ID: 28095876
[TBL] [Abstract][Full Text] [Related]
4. A multicriteria decision analysis (MCDA) tool to purchase implantable medical devices in Egypt.
Elezbawy B; Fasseeh AN; Németh B; Gamal M; Eldebeiky M; Refaat R; Taha A; Rabiea S; Abdallah M; Ramadan S; Noaman H; Eldin AB; Mostafa H; Nouh S; Zaki A; Abdelrahman M; Abaza S; Kalò Z
BMC Med Inform Decis Mak; 2022 Nov; 22(1):289. PubMed ID: 36352382
[TBL] [Abstract][Full Text] [Related]
5. Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?
Baran-Kooiker A; Czech M; Kooiker C
Front Public Health; 2018; 6():287. PubMed ID: 30374435
[No Abstract] [Full Text] [Related]
6. Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs.
Iskrov G; Miteva-Katrandzhieva T; Stefanov R
Front Public Health; 2016; 4():214. PubMed ID: 27747207
[TBL] [Abstract][Full Text] [Related]
7. Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases.
Schey C; Postma MJ; Krabbe PFM; Topachevskyi O; Volovyk A; Connolly M
Front Public Health; 2020; 8():162. PubMed ID: 32457865
[No Abstract] [Full Text] [Related]
8. A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study).
de Andrés-Nogales F; Cruz E; Calleja MÁ; Delgado O; Gorgas MQ; Espín J; Mestre-Ferrándiz J; Palau F; Ancochea A; Arce R; Domínguez-Hernández R; Casado MÁ;
Orphanet J Rare Dis; 2021 Apr; 16(1):186. PubMed ID: 33902672
[TBL] [Abstract][Full Text] [Related]
9. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
[No Abstract] [Full Text] [Related]
10. Recommendation for a Pilot MCDA Tool to Support the Value-Based Purchasing of Generic Medicines in the UAE.
Farghaly MN; Al Dallal SAM; Fasseeh AN; Monsef NA; Suliman EAMA; Tahoun MA; Abaza S; Kaló Z
Front Pharmacol; 2021; 12():680737. PubMed ID: 34168564
[No Abstract] [Full Text] [Related]
11. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.
Kolasa K; Zwolinski KM; Kalo Z; Hermanowski T
Orphanet J Rare Dis; 2016 Mar; 11():23. PubMed ID: 26965710
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA).
Villanueva V; Carreño M; Gil-Nagel A; Serrano-Castro PJ; Serratosa JM; Toledo M; Álvarez-Barón E; Gil A; Subías-Labazuy S
Epilepsy Behav; 2021 Sep; 122():108222. PubMed ID: 34371462
[TBL] [Abstract][Full Text] [Related]
14. How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.
Blonda A; Denier Y; Huys I; Simoens S
Front Pharmacol; 2021; 12():631527. PubMed ID: 34054519
[No Abstract] [Full Text] [Related]
15. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
[TBL] [Abstract][Full Text] [Related]
16. DRUG EVALUATION AND DECISION MAKING IN CATALONIA: DEVELOPMENT AND VALIDATION OF A METHODOLOGICAL FRAMEWORK BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR ORPHAN DRUGS.
Gilabert-Perramon A; Torrent-Farnell J; Catalan A; Prat A; Fontanet M; Puig-Peiró R; Merino-Montero S; Khoury H; Goetghebeur MM; Badia X
Int J Technol Assess Health Care; 2017 Jan; 33(1):111-120. PubMed ID: 28434413
[TBL] [Abstract][Full Text] [Related]
17. Can multi-criteria decision analysis (MCDA) be implemented into real-world drug decision-making processes? A Canadian provincial experience.
Laba TL; Jiwani B; Crossland R; Mitton C
Int J Technol Assess Health Care; 2020 Aug; ():1-6. PubMed ID: 32762789
[TBL] [Abstract][Full Text] [Related]
18. Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review.
Zelei T; Mendola ND; Elezbawy B; Németh B; Campbell JD
Pharmacoecon Open; 2021 Dec; 5(4):605-612. PubMed ID: 34003484
[TBL] [Abstract][Full Text] [Related]
19. A Step Toward the Development of the First National Multi-Criteria Decision Analysis Framework to Support Healthcare Decision Making in Saudi Arabia.
Al-Jedai A; Almudaiheem H; Alruthia Y; Althemery A; Alabdulkarim H; Ojeil R; Alrumaih A; AlGhannam S; AlMutairi A; Hasnan Z
Value Health Reg Issues; 2024 May; 41():100-107. PubMed ID: 38306770
[TBL] [Abstract][Full Text] [Related]
20. Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis.
Kolasa K; Zwolinski KM; Zah V; Kaló Z; Lewandowski T
Orphanet J Rare Dis; 2018 Apr; 13(1):67. PubMed ID: 29703227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
